Fc-Peptide Hybrid Molecule for Selective Autoimmune Dermatitis Targeting

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for autoimmune dermatitis, such as systemic corticosteroids and immunosuppressive drugs, lack specificity and can cause severe side effects, while anti-CD20 antibodies do not target autoreactive B-cells effectively.

Innovation Solution

A hybrid molecule comprising an antibody Fc fragment covalently bonded to a peptide that targets autoreactive lymphocyte receptors, specifically B-lymphocyte (BCR) or T-lymphocyte (TCR), to eliminate pathogenic autoantibodies and autoreactive T-lymphocytes through ADCC, phagocytosis, and complement activation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If systemic corticosteroids or immunosuppressive drugs are administered to treat autoimmune dermatitis, then the symptoms are suppressed, but severe side effects occur due to lack of specificity

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The invention segments the treatment approach by creating a hybrid molecule that specifically targets autoreactive lymphocytes rather than suppressing the entire immune system. The hybrid molecule consists of a peptide component that recognizes autoreactive lymphocyte receptors and an Fc fragment component that recruits immune effector cells, achieving selective elimination of pathogenic cells while sparing normal immune function.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The hybrid molecule applies local quality by concentrating therapeutic action specifically at autoreactive lymphocytes through the peptide component's selective binding to autoreactive BCRs or TCRs. This localized targeting ensures that immunosuppressive effects are confined to pathogenic cells rather than affecting the whole immune system, thereby reducing systemic side effects.

Inventive Principle:

Principle #3Local quality

2Reliability

If anti-CD20 antibodies are used to target B-cells, then some B-cell activity is reduced, but autoreactive B-cells are not effectively targeted

Engineering Contradiction:

ImproveB-cell targetingVSAvoidspecificity for autoreactive cells

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The peptide component of the hybrid molecule exhibits local quality by specifically recognizing epitopes on autoreactive BCRs or TCRs, thereby distinguishing autoreactive lymphocytes from normal B-cells. This specific recognition ensures that only pathogenic cells are targeted for elimination, achieving both effective B-cell targeting and high precision in identifying autoreactive cells.

Inventive Principle:

Principle #3Local quality

3Measurement precision

If a hybrid molecule is designed to specifically target autoreactive lymphocytes, then treatment precision is improved, but molecular complexity increases

Engineering Contradiction:

Improvetargeting specificityVSAvoidmolecule structure

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The hybrid molecule employs the composite materials principle by combining two distinct functional components: a peptide component for specific recognition of autoreactive lymphocyte receptors and an Fc fragment component for recruiting immune effector cells. This composite structure integrates the advantages of both components, achieving high targeting precision while leveraging well-understood immunological mechanisms.

Inventive Principle:

Principle #40Composite materials

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The hybrid molecule effectively targets and eliminates autoreactive lymphocytes, reducing autoimmune dermatitis symptoms by specifically addressing the source of autoantibodies and pro-inflammatory cytokines, offering a more targeted treatment with fewer side effects.

Implementation Method 1

which will then be eliminated, after binding the Fc fragment to the Fc receptors, by macrophages (via phagocytosis) and/or NK-cells (via antibody-dependent cell-mediated cytotoxicity—ADCC)

Methodology Applied

Scientific EffectAntibody-dependent cell-mediated cytotoxicity (ADCC):

Implementation Method 2

by macrophages (via phagocytosis) and/or NK-cells (via antibody-dependent cell-mediated cytotoxicity—ADCC), and/or by complement cascade activation

Methodology Applied

Scientific EffectComplement cascade activation:

Implementation Method 3

which will then be eliminated, after binding the Fc fragment to the Fc receptors, by macrophages (via phagocytosis)

Methodology Applied

Scientific EffectPhagocytosis:

Data Source

PatentUS20260091122A1Hybrid Molecule Comprising an Antibody FC Portion and at Least One Peptide Binding to a Self-Reactive Lymphocyte Involved in Autoimmune Dermatitis, and Uses Thereof

Publication Date: 2026.04.02 ARTHRITIS RECHERCHE & DEV

AI summary

The invention relates to a hybrid molecule comprising at least one antibody Fc fragment covalently bonded to at least one peptide bonding to an autoreactive lymphocyte, responsible for autoimmune dermatitis, the uses of such a hybrid molecule, as well as the production method thereof.